Mike Boken, Shire
S
Michael Burke, Ovation
Barry Greene, Alnylam
Malvinder Singh, Ranbaxy Labs
Sean McLoughlin, GlaxoSmithKline
Ludwig Hantson, Novartis
Everybody's Right
The great debate on DTC advertising is heating up again. We're going to be hearing a lot about fair balance and risk communication and costs. But what about the patients?
David Newman, GlaxoSmithKline
Jeffrey Aronin, Ovation
Vlad Hogenhuis, Merck
Safi Bahcall, Synta Pharmaceuticals
Alan Tennenberg; Tibotec, J&J
Greg Parekh, Novartis
J. Martin Jernigan, Novo Nordisk
The Buddy System
Jean-Marc Niemetz on forming partnerships with the industry's major stakeholders
Blair Gibson, Merck
Julie McHugh, J&J
Rich Tillyer, Merck
Jared Silverman, Cubist
Ameet Mallik, Novartis
John Orwin, Genentech
Angela Moskow, Sanofi-Aventis
Tariq Arshad, Pfizer
Suzanne Delaney, AstraZeneca
Susanne Schaffert, Novartis
Candidates Target Pharma
US presidential hopefuls look to comparative effectiveness analysis to address price and access issues
Evan Morris, Roche
Chris Claiborne, Millennium
Rob Perez, EVP and COO, Cubist Pharmaceuticals
John Shamsey, Bristol-Myers Squibb
